Belda-Hofheinz, S. (Sylvia)

Filtering

2020 - 20222

Settings

Author search.filters.isAuthorOfPublication.5319404b-588c-423d-827d-6d63ec7b8602

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Which is the best route to achieve nutritional goals in pediatric ECMO patients?
    (Elsevier, 2022) Belda-Hofheinz, S. (Sylvia); Martín-Arriscado-Arroba, C. (Cristina); Germán-Díaz, M. (Marta); Oviedo-Melgares, L. (Lidia); López-Fernández, E. (Eduardo); Núñez-Ramos, R. (Raquel); Moreno-Villares, J.M. (José Manuel)
    Objectives: Estimating caloric intake and choosing route of administration are fundamental in the nutritional support of patients being supported by extracorporeal membrane oxygenation (ECMO). The aim of this study was to review the nutritional intervention carried out in a pediatric cohort in a third-level hospital. Methods: This was a prospective descriptive study. Age, sex, underlying pathology, Pediatric Risk of Mortality score, ECMO indication, type of care, duration of ECMO support, and prognosis were collected. Type of nutritional support, route of administration, kcal/kg achieved, estimated energy requirements, and percentage of caloric objective (%CO) reached on days 3 and 5 after cannulation were recorded. Results: Twenty-four venoarterial ECMO runs in 23 patients over a period of 2 y were recorded. Of the 23 patients, 15 were <1 y of age. The underlying pathology in 56.5% was cardiac disease. Three groups were identified: parenteral nutrition (group 0, n = 7), enteral nutrition (group 1, n = 8), and mixed nutrition (group 2, n = 7). The median of the %CO was 33.34 (0 84) on day 3 and 87.75% (78.4 100) on day 5 of ECMO, respectively for group 0; 75.5 (42.25 98.5) and 85% (24.4 107.7) in group 1 and 68.7 (44.4 82.2) and 91.2% (35.5 92) in group 2 (P > 0.05). Children <12 mo of age and cardiac patients represented 85.71% and 71.43% of total patients in group 0. Among the eight episodes of exclusive enteral nutrition, no complications were identified. Conclusion: Enteral nutrition appears to be safe in the setting of hemodynamic stability and absence of contraindications and is equivalent to other nutritional interventions in terms of compliance with estimated energy requirements.
  • Thumbnail Image
    Severe manifestations of SARS-CoV-2 in children and adolescents: from COVID-19 pneumonia to multisystem inflammatory syndrome: a multicentre study in pediatric intensive care units in Spain
    (Springer Nature, 2020) Leóz-Gordillo, I. (Inés); Belda-Hofheinz, S. (Sylvia); Medina-Ramos, L. (Laura); Gutierrez-Jimeno, M. (Miriam); Sánchez-Ganfornina, I. (Inma); Hernández-Palomo, R.M. (Rosa María); Medina-Monzón, C. (Carmen); Huidobro-Labarga, B. (Beatriz); Oulego-Erróz, I. (Ignacio); López‑Herce-Cid, J. (Jesús); García‑Besteiro, M. (María); Holanda-Peña, M.S. (María Soledad); Vázquez-Martínez, J.L. (José Luís); González-Cortés, R. (Rafael); Flores-González, J.C. (José Carlos); Cuervas‑Mons-Tejedor, M. (Maite); Slöcker-Barrio, M. (Maria); Carlos-Vicente, J.C. (Juan Carlos) de; Fernández-Romero, E. (Emilia); García‑Salido, A. (Alberto); Hernández-Yuste, A. (Alexandra); Guitart-Pardellans, C. (Carmina); Sorribes-Ortí, C. (Clara); Trastoy-Quintela, J. (Javier); Balcells-Ramírez, J. (Joan); Antón, J. (Javier)
    Background Multisystem inflammatory syndrome temporally associated with COVID-19 (MIS-C) has been described as a novel and often severe presentation of SARS-CoV-2 infection in children. We aimed to describe the characteristics of children admitted to Pediatric Intensive Care Units (PICUs) presenting with MIS-C in comparison with those admitted with SARS-CoV-2 infection with other features such as COVID-19 pneumonia. Methods A multicentric prospective national registry including 47 PICUs was carried out. Data from children admitted with confirmed SARS-CoV-2 infection or fulfilling MIS-C criteria (with or without SARS-CoV-2 PCR confirmation) were collected. Clinical, laboratory and therapeutic features between MIS-C and non-MIS-C patients were compared. Results Seventy-four children were recruited. Sixty-one percent met MIS-C definition. MIS-C patients were older than non-MIS-C patients (p = 0.002): 9.4 years (IQR 5.5–11.8) vs 3.4 years (IQR 0.4–9.4). A higher proportion of them had no previous medical history of interest (88.2% vs 51.7%, p = 0.005). Non-MIS-C patients presented more frequently with respiratory distress (60.7% vs 13.3%, p < 0.001). MIS-C patients showed higher prevalence of fever (95.6% vs 64.3%, p < 0.001), diarrhea (66.7% vs 11.5%, p < 0.001), vomits (71.1% vs 23.1%, p = 0.001), fatigue (65.9% vs 36%, p = 0.016), shock (84.4% vs 13.8%, p < 0.001) and cardiac dysfunction (53.3% vs 10.3%, p = 0.001). MIS-C group had a lower lymphocyte count (p < 0.001) and LDH (p = 0.001) but higher neutrophil count (p = 0.045), neutrophil/lymphocyte ratio (p < 0.001), C-reactive protein (p < 0.001) and procalcitonin (p < 0.001). Patients in the MIS-C group were less likely to receive invasive ventilation (13.3% vs 41.4%, p = 0.005) but were more often treated with vasoactive drugs (66.7% vs 24.1%, p < 0.001), corticosteroids (80% vs 44.8%, p = 0.003) and immunoglobulins (51.1% vs 6.9%, p < 0.001). Most patients were discharged from PICU by the end of data collection with a median length of stay of 5 days (IQR 2.5–8 days) in the MIS-C group. Three patients died, none of them belonged to the MIS-C group. Conclusions MIS-C seems to be the most frequent presentation among critically ill children with SARS-CoV-2 infection. MIS-C patients are older and usually healthy. They show a higher prevalence of gastrointestinal symptoms and shock and are more likely to receive vasoactive drugs and immunomodulators and less likely to need mechanical ventilation than non-MIS-C patients.